Rensselaer, NY (PRWEB) July 2, 2010
Because chronic inflammation of the hair follicle is considered a contributing factor in the onset and progression of common pattern hair loss, study investigators Sridar Chittur, Brian Parr & Geno Marcovici sought to measure the test material's activity in blocking key markers of pathologic inflammation by using a well-validated molecular assay representative of hair follicle keratinocytes. Specifically, the research team found that the test compound suppressed gene expression of several inflammatory chemokines potentially linked to hair loss.
Hair loss affects over forty million American men and twenty million American women. The hair loss treatment industry represents a multi-billion dollar revenue stream annually.
In addition to anti-inflammatory agents, TS050508A was formulated with a subset of botanically derived, highly potent DHT inhibitors. DHT is a well-known trigger of pattern hair loss. Thus, by combining targeted anti-inflammatory agents with potent DHT inhibitors the test composition has been designed to offer enhanced clinical efficacy over conventional monotherapy.
Lead scientist for the study Sridar Chittur, Ph.D. has been at the forefront of molecular research authoring published works ranging from degenerative mitral valve disease (DMVD), to transcriptional changes associated with oxidative stress in the mitochondria. Co-author Brian Parr, Ph.D. brings a wealth of basic science expertise to the project with a number of peer-reviewed papers describing novel gene transcription and protein expression profiles in the Wnt and Frizzled pathways.
Study co-author Geno Marcovici, Ph.D. has been active in the hair loss field for more than a decade. His research efforts include the first published clinical trial successfully testing naturally derived 5 alpha reductase inhibitors in the setting of pattern hair loss. Explaining the importance of validating ART's proprietary formulations Marcovici notes that "[a]side from HairGenesis®, the naturally-derived hair treatments commercially available offer little or no objective evidence that they work. On the other hand, the drug-based treatments that do work come with potentially serious negative side effects. This tends to render HairGenesis® a unique proposition in the category. "
With a cited reference impact factor of 2.535, the international, peer-reviewed journal Evidence-based Complementary and Alternative Medicine (eCAM) is widely considered to be among the most well-respected research publications in the ISI category of Integrative & Complementary Medicine. The Journal seeks to apply scientific rigor to the study of complementary and alternative medicine (CAM) modalities. eCAM emphasizes health outcome, while documenting biological mechanisms of action. The journal is devoted to the advancement of science in the field of basic research, clinical studies, methodology or scientific theory in diverse areas of Biomedical Sciences. eCAM is also noteworthy as a journal that makes the final published version of every NIH-funded paper publicly available in PubMed Central no later than 12 months after publication. Such deposits are in accord with the NIH Public Access Policy.
Link To New Hair Growth Formula Study
About The Center For Functional Genomics, SUNY
The Microarray Core Facility is a component of the University Of Albany Center for Functional Genomics and was established to provide the infrastructure to enable the development of major projects that utilize DNA microarrays for large-scale analysis of gene expression. The DNA Microarray Center currently employs two technologies for gene expression analysis: Affymetrix GeneChip arrays and custom-produced spotted cDNA microarrays. Projects developed through the DNA Microarray Center have made use of Affymetrix arrays from both eukaryotic as well as prokaryotic genomes. The Facility is also currently developing specialized custom printed arrays to examine gene expression in mouse tissues as part of a NIH funded Mutant Mouse Regional Resource Center.
About Advanced Restoration Technologies Inc., DBA HairGenesis®
Combining scientific validation with the safety of natural ingredients, ART's product line HairGenesis® represents a unique therapeutic platform in the hair loss treatment category. Prior to focusing on basic science research, ART established a 10-year track record as a surgical center for IRB-monitored clinical investigation, testing new drugs as well as medical devices. ART-based published studies include those undertaken on behalf of Organogenesis, Canton, MA and Procyte Corporation, Kirkland, WA. It was from this research platform that Hair Genesis™ was originally conceived and created.
Hair Genesis® is noteworthy as the first, and so far only, naturally derived hair loss treatment supported by published 3rd Party clinical and basic science research. Hair Genesis® is sold primarily through internet-based distribution (http://www.hairgenesis.com).
# # #